Interankle systolic blood pressure difference and renal outcomes in patients with chronic kidney disease

Szu-Chia Chen1,2,3,4, Yi-Chun Tsai1,3,4, Jiun-Chi Huang1,2

  • 1Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University.

Nephrology (Carlton, Vic.)
|September 16, 2015
PubMed

Insights

Increased interankle blood pressure difference is linked to faster kidney function decline and higher risk of kidney failure in chronic kidney disease (CKD) patients. This finding highlights a new indicator for renal progression in CKD.

Area of Science:

  • Nephrology
  • Cardiology
  • Vascular Medicine

Background:

  • Interankle blood pressure (BP) difference is a known marker for peripheral artery disease and cardiovascular events.
  • Its association with renal outcomes in chronic kidney disease (CKD) remains unevaluated.

Purpose of the Study:

  • To investigate the relationship between interankle BP difference and the rate of renal function decline.
  • To determine if interankle BP difference predicts progression to renal end points in patients with stage 3-5 CKD.

Main Methods:

  • 144 patients with stage 3-5 CKD had simultaneous BP measurements in all four limbs.
  • Renal function decline was assessed via estimated glomerular filtration rate (eGFR) slope.
  • Renal end points included a 25% eGFR decline or initiation of dialysis.

Main Results:

  • An elevated interankle systolic BP difference correlated with a worse eGFR slope.
  • Increased interankle BP difference was associated with rapid renal progression.
  • A higher interankle BP difference significantly increased the risk of progression to renal end points.

Conclusions:

  • Interankle systolic BP difference is a significant predictor of rapid renal progression in CKD patients.
  • This BP measurement may serve as a valuable tool for assessing renal prognosis in individuals with moderate to advanced CKD.
Abstract

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
627
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
494
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K